SIGA Technologies, Inc. (NASDAQ: SIGA) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $196M. The Maz Rating grades it against the other companies in its sector.
SIGA Technologies, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.73, SIGA Technologies, Inc. trades at 427.8x trailing earnings, 3.8x sales and 1.2x book value. Over the last twelve months it generated about $52M of revenue and $458528 of net income. It runs a gross margin of 54.0%, an operating margin of -14.2% and a net margin of 1.4%. It shows return on equity of 0.4%, return on invested capital of 1.2% and a free cash flow yield of -5.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 24.57. Over the past 52 weeks the share price ranged from $2.66 to $7.11, with a beta of 1.02.
SIGA Technologies, Inc. pays a dividend yielding 21.91%, with 6061% of earnings paid out. Its Maz Dividend Score is 1.77 out of 5, ranked against the other dividend payers in its sector (Safety 1.43, Growth 4.03, Yield 4.63, Consistency 1.17).
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, SIGA Technologies, Inc. (SIGA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 51.6% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 51.6% / 33% · Receivables / Mkt Cap (36m) 0.89% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 51.6% / 33.33% · Receivables / Mkt Cap (24m) 0.89% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.07% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 67.9% / 33.33% · Receivables / Avg Assets (4Q) 2.15% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 67.4% / 33.33% · (Cash+Recv) / Total Assets 68.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, SIGA Technologies, Inc. (SIGA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. SIGA Technologies, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
SIGA Technologies, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.